Results 121 to 130 of about 27,278 (203)
Sarcopenic Obesity in Metabolic and Bariatric Surgery: A Scoping Review
ABSTRACT The risk of sarcopenic obesity (SO), characterized by the coexistence of excess adiposity and low muscle mass and function, may be increased in metabolic and bariatric surgery (MBS). There is a possibility of SO development after surgery, but also aggravation of pre‐existing SO, a hidden condition associated with poor health‐related outcomes ...
Flavio T. Vieira+7 more
wiley +1 more source
Weight Loss‐Associated Remodeling of Adipose Tissue Immunometabolism
ABSTRACT Obesity is a multifactorial condition characterized by excessive adiposity and systemic chronic low‐grade inflammation. Recent literature reflects a growing appreciation for the complex interplay between metabolism and the immune system in the pathogenesis of obesity‐related health conditions.
Paulo José Basso+5 more
wiley +1 more source
Introduction: Evidence indicates that morphine impairs memory process. Ghrelin hormone has been linked to learning and memory processes and modulates reward properties of addictive drugs.
Soudabe Dastjani-Farahani+2 more
doaj
The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies
ABSTRACT Obesity is a chronic metabolic disease characterized by disturbances in energy homeostasis, leading to excessive fat accumulation. The pathogenesis of the disease is shaped by a complex interplay of genetic, epigenetic, biological, psychological, and environmental factors.
Gašper Tonin+6 more
wiley +1 more source
The role of agomelatine in appetite regulation and body weight in rats
Abstract The hypothalamic nuclei play a central role in the synthesis of anorexigenic and orexigenic neuropeptides, which are regulated by peripheral hormones, like leptin and ghrelin. Melatonergic receptors (MT1/MT2) are prominently expressed in the arcuate nucleus of the hypothalamus – an essential hub for appetite control – and in peripheral ...
Engin Korkmaz+3 more
wiley +1 more source
Abstract figure legend The incretin system in obesity. The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) (yellow) and glucagon‐like peptide‐1 (GLP‐1) (blue) are produced by the proximal and distal small intestinal epithelium, where they are released postprandially into the bloodstream to modulate a myriad of physiological and ...
Constanza Alcaino+2 more
wiley +1 more source
Oxyntomodulin physiology and its therapeutic development in obesity and associated complications
Abstract figure legend Physiological influences of OXM and its emerging insights from evidence on bariatric surgery effects. CCK, cholecystokinin; FGF21, fibroblast growth factor 21; GLUT4, glucose transporter type 4; IRS1, insulin receptor substrate‐1; NNMT, nicotinamide N‐methyltransferase; OXM, oxyntomodulin Abstract Incretins, such as glucagon‐like
Martin T. W. Kueh+3 more
wiley +1 more source
Abstract figure legend Here we construct an anatomical map of brainstem projections to the ventral tegmental area (VTA) and investigate the neurochemical and neurophysiological nature of these VTA‐projecting nucleus of the solitary tract (NTS) neurons.
Caitlin R. Ritchey+2 more
wiley +1 more source
Low‐ or No‐Energy Sweeteners and Body Weight Management: Dissecting a “Minor” Effect
ABSTRACT Nonnutritive sweeteners were introduced on the market over a century ago to displace the calories of added sugars in foods and beverages and, therefore, facilitate weight loss. In spite of their widespread use, obesity has reached epidemic proportions. The present paper addresses this apparent paradox. Low‐ or no‐energy sweeteners (LNES) are a
France Bellisle
wiley +1 more source